Ipsen SA – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen SA – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights
and shares composing the share capital
Ipsen SA – Monthly information relative to the total number of voting rights and shares composing the share capital
- 10 March 2023 - 1 mins read
Monthly information relative to the total number of voting rights
and shares composing the share capital
Related Press Releases
17 April 2024
4 mins read
Ipsen publishes its 2023 Universal Registration Document
08 April 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
02 April 2024
7 mins read
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
07 March 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
15 February 2024
1 mins read
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
13 February 2024
14 mins read
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
08 February 2024
8 mins read
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
06 February 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
22 January 2024
10 mins read
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
08 January 2024
1 mins read